Premium
Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma
Author(s) -
HarkerMurray Paul D.,
Drachtman Richard A.,
Hodgson David C.,
Chauvenet Allen Russell,
Kelly Kara M.,
Cole Peter David
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24851
Subject(s) - medicine , lymphoma , oncology , hodgkin lymphoma , chemotherapy , risk stratification , regimen , refractory (planetary science) , hematopoietic stem cell transplantation , radiation therapy , transplantation , physics , astrobiology
Risk‐adapted, response‐based therapies for pediatric Hodgkin lymphoma have resulted in 5‐year survival exceeding 90%. Although high‐dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk‐stratified, response‐based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579–586. © 2013 Wiley Periodicals, Inc.